Tag Archives: Breast cancer

Advisory Panel Rejects Avastin For Breast Cancer Treatment

By George Koroneos | Published: July 21, 2010
An FDA advisory panel on Tuesday voted 12–1 to discontinue Avastin (bevacizumab) as a treatment for advanced breast cancer due to post-market studies stating that the treatment does not to increase patient lifespan by any significant length of time. This is a huge problem for Roche who purchased the treatment as part of its merger with [...]
Posted in FDA, Safety | Also tagged , , , , , , , | 1 Comment

Judge Spikes Myriad Genetic’s Control of Genes

By George Koroneos | Published: March 30, 2010
Image via Wikipedia Score one for nature. A US district court judge on Monday declared that pharma companies can’t patent individual genes because they are they are not, in fact, creating them. Last spring, Myriad Genetics was taken to task by the ACLU for monopolizing a patent it had discovered for breast cancer. The civil rights group [...]
Posted in Biotech, News | Also tagged , , , , , , | 1 Comment

Q&A with Steven Paul: Lilly’s New Development Plan

By George Koroneos | Published: September 23, 2009
Last week, Lilly announced a major restructuring plan focused around the creation of one Developmental Center of Excellence and several individual business units. The media (Pharm Exec included) focused on the news that 5,500 jobs were being cut as part of the plan. This week, we’re talking to Lilly to find out what the company’s [...]
Posted in Strategy | Also tagged , , , , , , | 3 Comments

NICE Stats Spur Controversy and Back Patting

By Sarah Houlton | Published: September 23, 2009
The UK’s National Health Service has released its first statistics that show how NICE approval has affected medicines uptake in the UK. The NHS Information Centre’s Metrics Working Group looked at 26 medicines that the NICE has said should be reimbursed and how they were prescribed in 2008. It then compared the actual usage with [...]
Posted in Strategy | Also tagged , , , , , , | Leave a comment

Lilly Osteoporosis Drug Canned in Phase III Trials

By George Koroneos | Published: August 19, 2009
Image by go elsewhere… via Flickr Lilly, on Wednesday, announced that it would not seek regulatory approval for its osteoporosis treatment arzoxifene, because the drug failed to meet certain end points in Phase III clinical trials. The good news is that the drug was successful in meeting the primary end point of the trial, dubbed “GENERATIONS.” [...]
Posted in Strategy | Also tagged , , , , , | 1 Comment